JP2024517431A5 - - Google Patents
Info
- Publication number
- JP2024517431A5 JP2024517431A5 JP2023565206A JP2023565206A JP2024517431A5 JP 2024517431 A5 JP2024517431 A5 JP 2024517431A5 JP 2023565206 A JP2023565206 A JP 2023565206A JP 2023565206 A JP2023565206 A JP 2023565206A JP 2024517431 A5 JP2024517431 A5 JP 2024517431A5
- Authority
- JP
- Japan
- Prior art keywords
- ray powder
- powder diffraction
- solid
- exhibiting
- solid form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178752P | 2021-04-23 | 2021-04-23 | |
| US63/178,752 | 2021-04-23 | ||
| PCT/US2022/025815 WO2022226221A1 (en) | 2021-04-23 | 2022-04-21 | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024517431A JP2024517431A (ja) | 2024-04-22 |
| JP2024517431A5 true JP2024517431A5 (https=) | 2025-05-02 |
| JP7825636B2 JP7825636B2 (ja) | 2026-03-06 |
Family
ID=83723159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565206A Active JP7825636B2 (ja) | 2021-04-23 | 2022-04-21 | （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240208931A1 (https=) |
| EP (1) | EP4326255A4 (https=) |
| JP (1) | JP7825636B2 (https=) |
| KR (1) | KR20240000540A (https=) |
| CN (1) | CN117529313A (https=) |
| AU (1) | AU2022261159A1 (https=) |
| BR (1) | BR112023021916A2 (https=) |
| CA (1) | CA3216258A1 (https=) |
| IL (1) | IL307910A (https=) |
| MX (1) | MX2023012521A (https=) |
| WO (1) | WO2022226221A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7626910B2 (ja) | 2019-10-24 | 2025-02-05 | ピエール ファーブル メディカモン | Ｒａｆキナーゼの阻害剤 |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| BR112023021913A2 (pt) | 2021-04-23 | 2024-01-16 | Kinnate Biopharma Inc | Tratamento de câncer com inibidor de raf |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) * | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| KR20210055042A (ko) * | 2018-07-31 | 2021-05-14 | 오스칸 그룹 홀딩스 엘티디 | “고체의 자가-유화 약학 조성물” |
| WO2020198058A1 (en) * | 2019-03-22 | 2020-10-01 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| TW202106684A (zh) * | 2019-05-03 | 2021-02-16 | 美商奇奈特生物製藥公司 | Raf激酶抑制劑 |
| JP7626910B2 (ja) * | 2019-10-24 | 2025-02-05 | ピエール ファーブル メディカモン | Ｒａｆキナーゼの阻害剤 |
-
2022
- 2022-04-21 EP EP22792520.3A patent/EP4326255A4/en active Pending
- 2022-04-21 IL IL307910A patent/IL307910A/en unknown
- 2022-04-21 US US18/556,243 patent/US20240208931A1/en active Pending
- 2022-04-21 JP JP2023565206A patent/JP7825636B2/ja active Active
- 2022-04-21 CN CN202280044060.6A patent/CN117529313A/zh active Pending
- 2022-04-21 MX MX2023012521A patent/MX2023012521A/es unknown
- 2022-04-21 BR BR112023021916A patent/BR112023021916A2/pt unknown
- 2022-04-21 KR KR1020237039724A patent/KR20240000540A/ko active Pending
- 2022-04-21 WO PCT/US2022/025815 patent/WO2022226221A1/en not_active Ceased
- 2022-04-21 CA CA3216258A patent/CA3216258A1/en active Pending
- 2022-04-21 AU AU2022261159A patent/AU2022261159A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024517431A5 (https=) | ||
| AU652046B2 (en) | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present | |
| US8414918B2 (en) | Stable imatinib compositions | |
| JP4931874B2 (ja) | リモナバントの結晶多形の製造方法 | |
| JPH05140103A (ja) | 新規なｎ−アルキレンピペリジノ化合物及びそのエナンチオマー；これらを合成する方法及びこれらを含む医薬品組成物 | |
| JP2018168180A (ja) | バルサルタンおよびａｈｕ−３７７を含む三ナトリウム塩超分子複合体の新規な結晶形及びその製造方法 | |
| US20100010098A1 (en) | Polymorphs of rasagiline hydrochloride | |
| JP2025179094A5 (https=) | ||
| JP2022532404A5 (https=) | ||
| JP2023548160A (ja) | １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸の結晶性粒子の製造方法およびそれを含む薬学的組成物 | |
| JP7825636B2 (ja) | （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態 | |
| JP2007509143A5 (https=) | ||
| AU2017254950B2 (en) | Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein | |
| JP4278652B2 (ja) | 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物 | |
| US20040266791A1 (en) | Water soluble salts of risperidone | |
| US20060252797A1 (en) | Receptor regulator | |
| JP2021529805A5 (https=) | ||
| TW200900392A (en) | Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same | |
| JP2024542840A5 (https=) | ||
| HUP0402553A2 (hu) | Venlafaxin-hidroklorid-monohidrát, eljárások előállítására, az ezt tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| JP7226697B2 (ja) | ブロナンセリン含有錠剤 | |
| RU2574405C2 (ru) | Твердые пероральные составы и кристаллические формы ингибитора белка апоптоза | |
| JP2008195654A (ja) | ベンゾ［ｂ］フラン化合物の新規結晶形 | |
| CZ2004124A3 (cs) | Název neuveden | |
| KR20060108696A (ko) | Ｌｔｂ4 길항제를 함유하는 약제학적 제형, 이의 제조방법및 이의 용도 |